

THE UNIVERSITY of EDINBURGH

Edinburgh Research Explorer

Investigating the use of data-driven artificial intelligence in computerised decision support systems for health and social care

Citation for published version:

Cresswell, K, Callaghan, M, Khan, S, Sheikh, Z, Mozaffar, H & Sheikh, A 2020, 'Investigating the use of data-driven artificial intelligence in computerised decision support systems for health and social care: Systematic review', *Health Informatics Journal*, pp. 1460458219900452. https://doi.org/10.1177/1460458219900452

Digital Object Identifier (DOI):

10.1177/1460458219900452

Link:

Link to publication record in Edinburgh Research Explorer

Document Version: Peer reviewed version

Published In: Health Informatics Journal

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Édinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Investigating the use of data-driven artificial intelligence in computerised decision support systems for health and social care: systematic review

Kathrin Cresswell, Chief Scientist Office Chancellor's Fellow, Director of Innovation, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, UK

Margaret Callaghan, Decision Support Evaluation Research Manager, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, UK

Sheraz Khan, PhD Student, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, UK

Zakariya Sheikh, Medical Student, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, UK

Hajar Mozaffar, Lecturer in Innovation, Business School, The University of Edinburgh, UK

Aziz Sheikh, Professor of Primary Care Research & Development and Director, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, UK

Correspondence to: K Cresswell, kathrin.beyer@ed.ac.uk

Abstract

Background: There is growing interest in the potential of artificial intelligence (AI) to support decision making in health and social care settings. There is, however currently limited evidence of the effectiveness of these systems.

Aims: To investigate the effectiveness of AI-based computerised decision support (CDS) systems in health and social care settings.

Methods: We conducted a systematic literature review to identify relevant randomised controlled trials (RCTs) conducted between 2013 and 2018. We searched the following databases: MEDLINE, EMBASE, CINAHL, Psychinfo, Web of Science, Cochrane Library, ASSIA, Emerald, Health Business Fulltext Elite, ProQuest Public Health, Social Care Online, and grey literature sources. Search terms were conceptualised into three groups: AI-related terms, CDS-related terms, and terms relating to health and social care. Terms within groups were combined using the Boolean operator OR, and groups were combined using the Boolean operator AND. Two reviewers independently screened studies against the eligibility criteria and then extracted data on eligible studies were extracted by two independent reviewers onto a customised sheet. The quality of studies was assessed through the Critical Appraisal Skills Programme (CASP) Checklist for RCTs. We then conducted an interpretive synthesis.

Findings: We identified 68 hits of which five studies satisfied the inclusion criteria. These studies varied substantially in relation to quality, settings, outcomes and technologies. None of the studies were conducted in social care settings and three RCTs showed no difference in patient outcomes. Of these, one investigated the use of Bayesian triage algorithms on forced expiratory volume in 1 second (FEV1) and health-related quality of life in lung transplant patients, one investigated the effect of image pattern recognition on neonatal development outcomes in pregnant women, and another investigated the effect of the Kalman filter technique for warfarin dosing suggestions on time in therapeutic range.

The remaining two RCTs, investigating computer vision and neural networks on medication adherence and the impact of learning algorithms on assessment time of patients with gestational diabetes, showed statistically significant and clinically important differences to the control groups receiving standard care. However, these studies tended to be of low quality lacking detailed descriptions of methods and only one study used a double-blind design.

Conclusions and implications: The evidence of effectiveness of AI to support decision making in health and social care settings is limited. Two of the trials demonstrated substantial potential health gains, but there were concerns in relation to the quality of these studies. It is unlikely that any single overall

message surrounding effectiveness will emerge – rather effectiveness of interventions is likely to be context specific.

Background

There is now an increasing focus on health information technology (HIT) to improve the quality, safety and efficiency of care, to tackle demographic shifts, variations in the quality of care, and ongoing concerns around safety, and cope with increasing economic pressures.(1) There is a growing empirical evidence base that knowledge-based computerised decision support (CDS), and in particular knowledge-based Clinical Decision Support Systems which form a subcategory of these, have the potential to improve practitioner performance.(2,3) Such technologies commonly draw on an existing knowledge base of existing research evidence and/or guidelines to provide logical reasoning-based expert advice. Knowledge-based CDS is different from data-driven CDS in that it does not involve the creation of new knowledge.

Recent reviews have shown that artificial intelligence (AI) algorithms in digital health interventions can be effective in improving health outcomes across a range of conditions but none has focused on data-driven CDS systems.(4,5) These systems are designed to emulate human performance typically by analysing large complex datasets. There are now over 16 AI-based products approved by the United States (US) Food and Drug Administration (FDA).¹

There is growing interest from the public, health service providers, policymakers, system vendors, the media and funding bodies, in the potential of CDS linked to data-driven AI-based algorithms as these can help to quantify risk and facilitate human decision making. However, there has to date been no systematic attempt to scope the empirical evidence base in relation to the effectiveness of CDS systems linked to data-driven AI-based algorithms and some have cautioned against the hype associated with AI-based technologies used in healthcare delivery.(6,7)

We aimed to investigate the effectiveness of data-driven AI to support decision making in health and social care settings.

Methods

Design

We undertook a systematic review of published empirical research. The systematic review protocol is registered with the PROSPERO International Prospective Register of Systematic Reviews and reported

¹ https://medium.com/syncedreview/ai-powered-fda-approved-medical-health-projects-a19aba7c681

using the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines.(8,9)

We used the PICO framework to form the research questions and to focus the literature search (see Table 1).

P (Population)	Health and social care users (patients and citizens), health and social care professionals and managers
l (Intervention)	AI-based CDS systems
C (Comparator(s))	Non-Al-based approaches
O (Outcomes)	Practitioner performance Patient, citizen and population outcomes Health system outcomes

Table 1: PICO framework for the review

Search strategy

We searched the published empirical literature from 2013 until September 2018 for work investigating AI to support decision making in health and social care settings. The start date was chosen as in 2013 IBM's Watson was first used in the medical field demonstrating the potential usefulness of AI algorithms in healthcare.(10)

We searched the following databases: MEDLINE, EMBASE, CINAHL, Psychinfo, Web of Science, Cochrane Library, ASSIA, Emerald, Health Business Fulltext Elite, ProQuest Public Health, Social Care Online, and grey literature sources. Search terms were divided into three groups: Al-related terms, CDS-related terms, and terms relating to health and social care settings. Terms within groups were combined using the Boolean operator OR, and groups were combined using the Boolean operator AND. We applied methodological filters to find randomised controlled trials (RCTs). Search strategies for each database can be viewed in Appendix 1.

Eligibility criteria

Studies were eligible for inclusion if they were conducted in health and social care settings and published in English; if they focused on AI; and if they used technological systems for clinical, managerial and self-management decision making.

Studies were excluded if they were not RCTs or if they fell outside our scope of interest. This included, for example, studies that evaluated technology that is not commonly associated with systems that are

driven by the analysis of patterns and models emerging from very large datasets, and those that did not focus on a combination of CDS and AI.

Study selection

Titles and abstracts of studies identified from the searches were screened by two investigators (MC and SK for abstracts, MC and ZS for full texts), who screened all retrieved potentially eligible studies independently against the above criteria. Any disagreements were resolved by discussion or, if necessary, through arbitration by KC.

Quality assessment and analysis

Formal quality assessment of eligible studies was undertaken independently by two reviewers (MC and ZS) using the Critical Appraisal Skills Programme (CASP) Checklist for RCTs.(11) Disagreements were resolved through discussion or, if necessary, through arbitration by KC.

Data extraction

Data were abstracted onto a customised data extraction sheet in Microsoft Excel by MC and ZS. Data were extracted on: authors, title, journal, year, country, healthcare setting, participant number and type, age, timescale, type of AI, type of decision support, comparator (non-AI/CDS based approaches), health problem/condition, outcomes assessed, impact on practitioner performance, impact on patient outcomes, impact on patient self-management, other estimates of effectiveness, enablers and barriers, reviewer notes, and reviewer interpretation.

Data analysis


A quantitative synthesis was judged to be inappropriate due to the heterogeneity of technologies being assessed and care contexts. Data were therefore descriptively summarised and narratively synthesised. We followed the following steps in conducting an interpretive synthesis of our findings: (1) describing the various functions of technological systems; (2) noting the context of the various studies and settings; (3) summarising evidence of effectiveness; and (4) summarising study quality.


Results

We identified 69 potentially eligible studies. After removing duplicates, we screened 68 abstracts. At screening stage, 31 abstracts were dropped. Most excluded abstracts (n=16) did not include AI. Study protocols (n=10) and non-randomized studies (n=10) were also excluded. We assessed 37 full-text articles for eligibility, from which 32 were excluded. Ineligible articles did not combine AI and CDS

functionality (n=15), did not have AI as their primary focus (n=7), did not have RCT designs (n=6), did not report our outcomes of interest (n=2), or did not have interventions that were data-driven (n=2) were excluded.

Five papers were included in final review (Figure 1). Of these, two were conducted in the US, one in Spain, one in Denmark, and one in the United Kingdom. Two included RCTs were conducted in inpatient settings, two in a home care setting, and one in an outpatient setting. Key characteristics of included studies are summarised in Table 2.





Author	Title	Source (Journa I)	Ye ar	Coun try of setti ng	Healt hcare settin g	Particip ant Number and type	Age	Time Scale	Type of AI if include	Type of decision support if included	Compa rator (non AI / CDS based approa ches)	Health proble m / conditi on	Outco mes assesse d	Impact on practiti oner perfor mance	Was the AI CDS approac h more successf ul	Impact on patient outcom es	Any impact on patient self- manage ment?	Other estimat es of effectiv eness	Oth er ena bles and barr iers
Caballero -Ruiz E, Garcia- Saez G, Rigla M, Villaplana M, Pons B, Hernando ME.	A web- based clinical decision support system for gestatio nal diabetes : Automat ic diet prescript ion and detectio n of insulin needs.	Interna tional Journal of Medica I Inform atics	20 17	Spai	Remo te - home	450 Pregnan t women	Not state d	17 mont hs	CDS to manage treatme nt of patient s with gestatio nal diabete s through teleme dicine	whether patient needed insulin therapy / or patient demonstr ate good metabolic control	Standa rd care	Gestati onal diabete s manag ed remote ly throug h teleme dicine and patient upload ed data	Access to speciali sed healthc are assistan ce, reduce the evaluati on time for patient s, and avoid gestatio nal diabete s adverse outcom es. Clinical time require d per patient number of face to face visits frequen	Assess ment time decrea sed by almost a third. Face to face reduce d by 88% but overall time the same, autom atic detecti on of 100% who needed insulin therap y and diet adjust ment	Yes	High patient satisfac tion (but wasn't compar ed to a control so basicall y saying that it is accepta ble to patient s)	Not explicitl y stated but if saves clinical time, saves patient time and travel from fewer visits and effectiv ely is a significa nt increase in self- manage ment		

												cy and duratio n of telemat ic reviews patient complia nce to self- monito ring patient satisfac tion					
Finkelstei n SM, Lindgren BR, Robiner W, Lindquist R, Hertz M, Carlin BP, et al.	A randomi zed controlle d trial compari ng health and quality of life of lung transpla nt recipient s followin g nurse and compute r-based triage utilizing home spiromet ry monitori ng. Telemed icine journal	Journal of the Americ an Teleme dicine Associa tion	20 13	USA	Inpati ent	65 lung transpla nt recipient s	37-69	Octob er 2006- April 2009 plus one year follow up	Compute r based Bayesian algorithm	Manua I nurse decisio n	Lung transpl ant	Effectiv eness of triaging clinical interve ntions in lung transpl ant recipien ts particip ating in home monito ring	No differe nces in outco mes measur ed. Change s from baselin e after year of forced expirat ory volume , SF36, QOL	No	None	No	

	and e- health																	
Infant Collabora tive Group.	Comput erised interpret ation of fetal heart rate during labour (INFANT) : a randomi sed controlle d trial. (10080): 1719- 29.	Lancet. 2017;3 89 North Americ an Edition	20 17	UK and Irela nd	Labou r Ward	women in labour 35+ weeks gestatio n having continuo us electroni c fetal monitori ng and number	16 or olde r	Jan 2010- Augus t 2013	Decisio n support softwar e	Interpret ation of cardiotoc ographs 'INFANT'	Usual care / no softwa re decisio n suppor t	Wome n in labour with continu ous electro nic fetal monito ring	NA	No differen ce	No differen ce in any neonat al outcom e of develop ment assess ment at age 2	NA	NA	NA

Labor ite	Listen	Chuelue	20		Outra	20	الم ما ا	10	Comment	Magazzalia	Nia	La ala a vasi	NIa	Vaa	Maga	Desuire	
Labovitz	Using	Stroke	20	USA	Outpa	28	"Adu	12	Comput	Measurin	No	Ischemi	No	Yes	Mean	Require	
DL,	Artificial		17		tient	adults	lts"	week	er	g &	daily	С	primary		cumula	S	
Shafner L,	Intellige				care	with	but		vision &	increasin	monito	stroke	outcom		tive	patients	
Reyes Gil	nce to					recently	age		neural	g	ring	&	e		adhere	to use	
М,	Reduce					diagnos	not		networ	medicatio		medica	specifie		nce	the	
Virmani	the Risk					ed	speci		ks	n		tion	d.		based	applicat	
D, Hanina	of					ischemic	fied			adherenc		adhere	Outcom		on the	ion to	
A.;a	Nonadh					stroke				e		nce	es were		AI	visually	
journal of	erence					receivin							mean		platfor	confirm	
cerebral	in					g any							cumula		m was	medicat	
circulatio	Patients					anticoag							tive		90.5%.	ion	
n.	on					ulation							adhere		Mean	ingestio	
2017;48(Anticoag												nce		cumula	n	
5):1416-	ulation												based		tive		
9.	Therapy												on the		adhere		
													AI		nce		
													platfor		indicate		
													m and		d by		
													adhere		plasma		
													nce		drug		
													based		concent		
													on		ration		
													plasma		was		
													concent		100%		
													ration		for the		
													levels		interve		
													and pill		ntion		
													count.		and		
													Subgro		50% for		
													up		the		
													analysis		control		
													was		group.		
													also		Mean		
													conduct		cumula		
													ed and		tive		
													the		adhere		
													same		nce		
													outcom		indicate		
													es were		d by pill		
															count		
													reporte d for		was		
															was 97.2%		
													patient				
													s who		for the		
													receive		interve		
													d		ntion		
													DOACs.		and		1

Image: Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. Sector of the control group. For the control group. <tr< th=""><th></th><th>- -</th><th></th><th> </th><th> </th><th></th><th> </th><th>I</th></tr<>		- -		 	 		 	I
control group, For patient s rececin BOACs, mean curve based on the Ai Ai Ai Ai Ai Ai Ai Ai Ai Ai Ai Ai Ai							90.6%	
control group, For patient s recein g DOACG, model, control g DOACG, model control g DOACG, control g DOACG, control g DOACG, control g DOACG, control g DOACG, control g DOACG, control g DOACG, control g DOACG, control g DOACG, control g DOACG, control g DOACG, control g DOACG, control g DOACG, control g DOACG, control g DOACG, control control g DOACG, control c							for the	
group. For patient s recein g DOACS, mean curula tive adhere on the Al platient g DOACS, mean curula tive adhere on the Al platforas mean curula tive adhere on the Al platforas mean curula tive adhere on the Al platforas mean curula tive adhere ndcare d by pill count was g6.4% for the interve nton adhere nterve adhere nterve nterve adhere nterve adhere adhere nterve adhere adhe								
For patient s patient s reccin B DACs, mean cumula tive adhere nce nce nce nce nce nce nce nce nce nc								
patient s s reccin B DOACS, mean cumulo twe adhere nee based on the Al Al pation patient cumulo twe based on the Al Al pation m vas 90.3%, mean cumulo twe based on the Al adhere noc musa gataro m vas 90.3%, mean cumulo twe adhere noc cumulo twe adhere noc s s d d d f d f d f d f d f d f d f d f							group.	
Image: sector of the sector								
Image: second							patient	
Image: second							S	
Image: second								
DOACS, mean cumula twe adhere acce based on the Al platfor m was 90.1%, mean cumula twe adhere acce 90.1%, mean cumula twe adhere nce indicate d b pill count was 96.4% of or the interve inte								
mean comula tive adhere nce based on the A platfor m was 90.1%, mean comula tive adhere nce indicate dorpail count was 95.4% for the interve ntion and 99.4% for the interve ntion and group and adhere nce interve tive adhere nce indicate dorpail count was 99.4% for the interve ntion and group and adhere nce interve tive adhere interve ntion and and group and adhere interve tive interve ntion and and and and and and and and and an							Б DOAC	
Image: Comula in the								
Image: Sector of the sector								
Image: Sector of the sector								
Image: Sector of the sector							tive	
Image: Source in the second of the second							adhere	
based on the Al platfor m was 90.1%, mean cumula tue adhere nce d by pill cumul was 90.1%, mean cumula tue adhere nce d by pill cumul was 93.1%, mean cumula tue adhere nce d by pill cumul was 95.1%, mean cumula tue adhere nce d by pill cumu								
Image: second							lice	
Al platfor m was 90.1%, mean cumula tive adhere nce indicate d by pill count d by pill count was 96.4% for the interve ntion and 90.9% for the interve ntion and group and mean cumula tive d by pill count was 96.4% for the interve ntion and group and mean cumula tive d by pill count was 90.9% for the interve ntion and group and mean cumula tive d by pill count was 90.9% for the interve ntion and group and mean cumula tive d by pill count was 90.9% for the interve ntion and mean cumula tive adhere ntion and d group and mean cumula tive adhere ntion and d group and mean cumula tive adhere ntion and d mean cumula tive adhere ntion and d mean cumula tive adhere ntion and d mean cumula tive adhere ntion and d mean cumula tive adhere adhere nce								
Image: second							on the	
Image: second							AI	
mean cumula time d by pill control group grou							platfor	
90.3%, mean umula tive adhere nce indicate d by pill count was 96.4% for the interve interve interve intion interve interve interve <							m was	
Image: Sector of the sector								
Image: second								
Image: second								
Image: second							cumula	
adhere nce indicate d by pill count was 96.4% for the interve ntion and and and and and and and an							tive	
Image: state in the state								
Image: Second								
d by pill count was 96.4% for the interve ntion and 90.9% for the control group and and and group and and tive control group and and dhee count ities and dhee count ities and dhee count ities and dhee count ities and and and and and and and and and and								
Image: second							indicate	
Image: second							d by pill	
Image: second							count	
96.4% for the interve and 90.9% for the control group and mean cumula tive adhere nce								
Image: state of the state							96.4%	
Image: Second								
Image: state of the state								
Image: state of the state								
Image: state of the state								
90.9% for the control group and mean cumula tive adhere nce								
Image: state of the state							90.9%	
Image: state stat							for the	
group and mean cumula tive adhere nce								
and mean cumula tive adhere nce								
and mean cumula tive adhere nce							group	
mean cumula tive adhere nce							and	
cumula tive adhere nce								
tive adhere nce								
adhere nce								
nce nce							tive	
							nce	
							indicate	

																d by plasma drug concent ration was 100% for the interve ntion and 33% for the control.			
Nielsen PB, Lundbye- Christens en S, van der Male M, Larsen TB.	Using a personal ized decision support algorith m for dosing in warfarin treatme nt: A randomi sed controlle d trial	Clinical Trials and Regulat ory Science in Cardiol ogy	20 17	Den mark	Home health settin g	191 participa nts	Mea n age of 65 year S	Patien ts enroll ed from Septe mber 2014 to Nove mber 2014 and then follow ed up for at least 90 days with a mean follow up of 140 days	Comput erized dosing algorith ms for warfari n. If a particip ant was allocate d to interve ntion, he/she would receive an algorith m- calculat ed dosage suggesti on.	Personali sed support for warfarin dosing (Kalman filter technique)	No AI algorit hm based suppor t - in contra st, the dosage sugges tion in the placeb o-arm would equal last week's dose of warfari n.	Eligible particip ants were patient s with an indicati on for warfari n treatm ent who were in steady state patient self manag ement (PSM) treatm ent	No interfac e with practiti oners - this group were on patient self manage ment (PSM) treatm ent	The interve ntion arm achiev ed a TTR of 81.6, while the placeb o arm attaine d a TTR of 80.9 (differe nce [interv ention arm minus placeb o arm]: 0.67 (95% confide nce interval -2.93 to 4.27)	The number of 'non- complia nt' registra tions (disagre ement with dosage suggesti on) was differen t in the two trial arms, average 15% per particip ant in the interve ntion arm and 6% in the placebo arm. Unable	"A second ary study measur e was the log- transfor med INR variabili ty. This method attemp ts to describ e the degree to which each individu al's INR value varies relative to his/her s previou s INR	Cannot identify any	No differe nce betwee n the two trial- arms in a high- quality warfari n treatm ent setup. Howev er in general , the model perfor med similarl y as to routine patient self- manag ement care.	

							to find	value.	
							clear	The	
								differen	
							pattern		
							or	ce in	
							reason	INR	
							for this	variabili	
								ty was	
								0.30	
								(0.14 to	
								0.47),	
								favouri	
								ng the	
								placebo	
								arm in	
								terms	
								of	
								lower	
								log	
								transfor	
								med	
								variabili	
								ty"	

Variation in study size, technological systems, timescales

We observed substantial variations in the size of studies (from 28 to 47062 participants), technological systems (i.e. type of AI-based CDS) and timescales over which the systems were assessed.(12-16) All included studies focused on specific patient populations (often with long-term conditions), namely: women with gestational diabetes,(12) women in labour,(14), adults with ischemic stroke,(15) thrombosis patients,(16) and lung transplant recipients.(13)

Types of AI facilitated decision support also varied widely. One study assessed learning algorithms to support patient self-management;(12) another study assessed algorithms facilitating automated triaging based on existing datasets;(13) and another study assessed algorithms facilitating the interpretation of fetal cardiotocographs (CTGs) through image pattern recognition.(14) The final two studies assessed the use of neural networks to facilitate medication adherence,(15) and the Kalman filter technique (an algorithm using temporal measurements) to personalise warfarin dosing recommendations for patient self-management.(16)

Three studies investigated decision making in patients, (12, 15, 16) whereas the others focused on decision making in healthcare professionals. (13, 14)

We further found large variations in timescales of studies from 12 weeks to 3.5 years in duration.(14,15)

Patient outcomes needed

In terms of outcomes, studies most frequently assessed impact of the intervention on patient outcomes, but these varied significantly across RCTs due to the differences in study populations. For example, Finkelstein and colleagues assessed forced expiratory volume in 1 second (FEV1) and health-related quality of life in lung transplant patients,(13) whilst others assessed neonatal development outcomes,(14) medication adherence,(15) and time in therapeutic warfarin range.(16) Two studies also assessed impacts on practitioner performance. These were RCTs examining the effectiveness of triaging interventions in lung transplant recipients,(13) and the impact on the clinician assessment time of patients.(12)

Caballero-Ruiz and colleagues applied a learning algorithm to a CDS to manage treatment of patients with gestational diabetes through telemedicine and compared this to standard care.(12) They assessed access to specialised healthcare, evaluation time for patients, adverse gestational diabetes outcomes, clinical time required per patient, number of face-to-face visits, frequency and duration of telematic reviews, patient compliance, and patient satisfaction.

Finkelstein et al investigated the effectiveness of a Bayesian triage algorithm for automated triaging based on analysing data from a home monitoring program in lung transplant patients, and assessed the effectiveness of triaging clinical interventions compared with manual nurse decision.(13)

The INFANT Collaborative Group tested the effectiveness of image pattern recognition in the interpretation of CTGs of women in labour and assessed neonatal outcomes of development at age 2 compared to usual care.(14)

A study conducted by Labovitz and colleagues assessed the effectiveness of computer vision and neural networks in improving medication adherence in patients with ischemic stroke and compared it with no daily monitoring.(15)

The final study conducted by Nielsen and colleagues assessed the effectiveness of an algorithm on warfarin dosing recommendations to patients to prevent thromboembolic events.(16) The control arm included no AI algorithm-based support, with the dosage suggestion equalling the previous week's dose of warfarin.

Quality assessment

The quality of studies was extremely variable. Details of methods were in some instances difficult to find and only one study used a double-blind design.(13) In another study, only patients were blinded,(16) another one used no blinding,(14) and for the remaining two it was unclear whether blinding took place.(12,15) We provide a risk of bias table below (Table 3).

Study	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other bias
Caballero- Ruiz et al 2017	Low risk	Low risk	Unclear	Unclear	High risk	High risk	High risk
Finkelstein et al 2013	Low risk	Low risk	Low risk	Unclear	Low risk	Low risk	Low risk

Table 3: Risk of bias table of included studies

Infant Collaborative Group 2017	Low risk	Low risk	High risk	Unclear	Low risk	Low risk	Low risk
Labovitz et al 2017	Unclear	Low risk	Unclear	Unclear	High risk	Unclear	High risk
Nielsen et al 2017	Low risk	Low risk	Low risk	Unclear	Low risk	Low risk	Low risk

Mixed evidence of effectiveness

Evidence of effectiveness was mixed, with two studies showing no statistically significant difference to the control group, (13,14) and two showing statistically significant and clinically relevant differences between the intervention and the control groups. (12,15,16) Detailed study characteristics and outcomes are provided in Table 2.

One study with high risk of bias, focussing on a learning algorithm to help with managing gestational diabetes reported positive findings. It showed a decrease in assessment time (from 15 minutes in the control group to 2.778 ± 0.858 minutes in the intervention group per patient), and a reduction in face-to-face consultations (3.207 ± 2.846 visits in the control group and 0.367 ± 0.901 in the intervention group).(12) Another study, also with high risk of bias, using computer vision and neural networks reported that the mean cumulative medication adherence indicated by plasma drug concentration was 100% for the intervention and 33% for the control group.(15)

Other RCTs with low risk of bias showed no difference. One trial using a Bayesian algorithm tool for remote monitoring, follow-up and triage of patients after lung transplants, reported no difference in the detection of changes in patients' FEV1 and quality of life between intervention and control groups.(13) Both groups showed non-significantly different decreases over two years, including a 2% FEV1 decrease (p= 0.721) at year 1 and a 3% decrease at year 2 (p= 0.861).

Another trial drawing on image pattern recognition for the computerised interpretation of CTGs during labour did not show an effect on neonatal outcomes.(14) Poor neonatal outcomes were reported in 172 (0.7%) babies in the AI-based CDS group versus 171 (0.7%) in control group.

A third trial showed no difference when comparing personalised algorithm generated warfarin dosing recommendations for thrombosis patients with standard care, showed that the intervention achieved

a time in the rapeutic range of 81.6, while the control group achieved 80.9 (difference: 0.67 (95% confidence interval -2.93 to 4.27). (16)

Discussion

Overall, the evidence of effectiveness of AI to support decision making in health and social care settings is limited. We found a very small number of relevant studies with large variability in quality, settings, outcomes and technologies. No identified studies were conducted in social care settings and none included work investigating any enablers and/or barriers for the use of data-driven AI to support decisions. Three RCTs showed no difference, whereas two showed statistically significant and clinically relevant differences to the control groups.

Strengths and limitations

Our review is a first of type examining the use of data-driven AI to support decision making. However, as we have shown, the number of potentially relevant RCTs is limited, perhaps reflecting the immaturity of the field, but also potentially due to overlapping definitions surrounding CDS and AI. For example, it was at times hard for the research team to distinguish between knowledge-driven and data-driven applications. Moreover, the conclusions that can be drawn from this work are limited as all included studies compared AI-based CDS with standard care. Ideally, the comparison should be AI-enabled CDS versus CDS to see if AI makes a difference to standard knowledge-based CDS.

Integration of findings with the current literature

The lack of eligible studies may call for widening the search criteria to include different methodologies to assess the effectiveness of data-driven AI algorithms to support decision making in health and social care settings.(17)

Nevertheless, despite these perhaps inevitable challenges, we have helped to provide a starting point for work in this area going forward. There is a need to look at potential unintended consequences and challenges associated with novel systems in combination with RCTs.(18) Concurrent qualitative evaluation can help to address some of these issues and also help to identify contextual dynamics and potential reasons for effectiveness (or lack thereof).(19)

It may be that the lack of existing RCTs in the area is due to issues with data access for AI specialists.(20) This may also help to explain the involvement of system developers in 50% of our included studies – they may have had privileged access to data in their systems. The more data algorithms can draw on, the more effective they become, but access to large curated datasets on which algorithms can be trained is currently still hard to achieve.(19,20)

17

More generally, there is a need to remember that, as in knowledge-driven CDS, the ultimate responsibility of the decision still lies with the human. As such, those at the receiving end of datadriven AI based CDS need to be trained to make decisions informed by these systems. This may require developing new skills and/or ways of considering evidence.(21)

Policy recommendations and implications for practice emerging from this work

Our work may support those cautioning against the assumed effectiveness of AI and the associated hype surrounding these technologies.(7) Policymakers need to be aware that evidence of effectiveness is limited at this stage. In order to address the variability of existing work in this area, strategic decision makers may need to extract key areas of focus for research and innovation within their locales where applications have the greatest potential to meet a major service need and where they are most likely to deliver real impact. Ideally, these should be designed to be comparable in terms of technologies and disease areas, and include qualitative formative evaluation components to capture emerging challenges. The limited details reported in the methods sections of included studies, particularly in relation to AI algorithms, also calls for clearer standards of reporting of studies to ensure rigour and independent assessment of risk of bias.

As the application of AI is gaining momentum, there is likely to be an increasing need for developing associated evaluation frameworks, reporting guidelines and understanding transferability beyond experimental contexts. A focus on unintended consequences, positive or negative, should be fundamental to these efforts.

Conclusions

Al-based data-driven decision making in healthcare settings may have significant potential. Two of the trials included in this work showed substantial gains, but there are concerns in relation to the quality of these studies.

Funding: This article has drawn on a programme of independent research funded by the Digital Health and Care Institute and Scottish Government. The views expressed are those of the author(s) and not necessarily those of the funders.

Acknowledgements: We gratefully acknowledge Healthcare Improvement Scotland's help with conducting the searches, and Dr Ann Wales' advice throughout the work.

References

- 1. Black AD, Car J, Pagliari C, Anandan C, Cresswell K, Bokun T, McKinstry B, Procter R, Majeed A, Sheikh A. The impact of eHealth on the quality and safety of health care: a systematic overview. PLoS medicine. 2011 Jan 18;8(1):e1000387.
- 2. Cresswell K, Majeed A, Bates DW, Sheikh A. Computerised decision support systems for healthcare professionals: an interpretative review. Journal of Innovation in Health Informatics. 2013 Mar 22;20(2):115-28.
- 3. Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Archives of internal medicine. 2003 Jun 23;163(12):1409-16.
- 4. Triantafyllidis AK, Tsanas A. Applications of Machine Learning in Real-Life Digital Health Interventions: Review of the Literature. Journal of Medical Internet Research. 2019;21(4):e12286
- 5. Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJ. Artificial intelligence in radiology. Nature Reviews Cancer. 2018 May 17:1.
- 6. Shortliffe EH, Sepúlveda MJ. Clinical decision support in the era of artificial intelligence. Jama. 2018 Dec 4;320(21):2199-200.
- Academy of Medical Royal Colleges. Artificial Intelligence in healthcare. Available from: http://www.aomrc.org.uk/reports-guidance/artificial-intelligence-in-healthcare/ (last accessed: 15/05/2019).
- 8. Available from: http://prisma-statement.org/ (last accessed: 28/04/2019).
- 9. Available from: http://www.crd.york.ac.uk/prospero (last accessed: 28/04/2019).
- 10. Ferrucci D, Levas A, Bagchi S, Gondek D, Mueller ET. Watson: beyond jeopardy!. Artificial Intelligence. 2013 Jun 1;199:93-105.
- 11. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org.
- 12. Caballero-Ruiz E, Garcia-Saez G, Rigla M, Villaplana M, Pons B, Hernando ME. A web-based clinical decision support system for gestational diabetes: Automatic diet prescription and detection of insulin needs. Int J Med Inf. 2017;102:35-49.
- 13. Finkelstein SM, Lindgren BR, Robiner W, Lindquist R, Hertz M, Carlin BP, et al. A randomized controlled trial comparing health and quality of life of lung transplant recipients following nurse and computer-based triage utilizing home spirometry monitoring. Telemedicine journal and e-health : the official journal of the American Telemedicine Association. 2013;19(12):897-903.
- 14. Infant Collaborative Group. Computerised interpretation of fetal heart rate during labour (INFANT): a randomised controlled trial. Lancet. 2017;389 North American Edition(10080):1719-29.
- 15. Labovitz DL, Shafner L, Reyes Gil M, Virmani D, Hanina A. Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy. Stroke; a journal of cerebral circulation. 2017;48(5):1416-9.
- Nielsen PB, Lundbye-Christensen S, van der Male M, Larsen TB. Using a personalized decision support algorithm for dosing in warfarin treatment: A randomised controlled trial. Clinical Trials and Regulatory Science in Cardiology. 2017;25:1-6.
- 17. Lilford RJ, Chilton PJ, Hemming K, Girling AJ, Taylor CA, Barach P. Evaluating policy and service interventions: framework to guide selection and interpretation of study end points. Bmj. 2010 Aug 27;341:c4413.

- 18. Stefanelli M. The socio-organizational age of artificial intelligence in medicine. Artificial intelligence in medicine. 2001 Aug 1;23(1):25-47.
- Avery, A.J., Rodgers, S., Cantrill, J.A., Armstrong, S., Cresswell, K., Eden, M., Elliott, R.A., Howard, R., Kendrick, D., Morris, C.J. and Prescott, R.J., 2012. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. The Lancet, 379(9823), pp.1310-1319.
- 20. Zhou L, Pan S, Wang J, Vasilakos AV. Machine learning on big data: Opportunities and challenges. Neurocomputing. 2017 May 10;237:350-61.
- 21. Jha S, Topol EJ. Adapting to artificial intelligence: radiologists and pathologists as information specialists. Jama. 2016 Dec 13;316(22):2353-4.

Appendix 1 – Search strategies

Database:	Saved search strategy	Search strategy (including limits and filters)
e.g. OVIDSP/Medline	name	
Medline	Artificial Intelligence Reviews	1. exp Artificial Intelligence/
		2. (artificial intelligence or AI).tw.
		3. ((comput* or artificial or machine) adj3
		intelligence).tw.
		4. exp Machine Learning/
		5. ((machine or artificial or deep) adj3 learning).tw.
		6. exp Algorithms/
		7. algorithm*.tw.
		8. (data driven or data-driven).tw.
		9. (computer adj3 (assist* or generat*)).tw.
		10. neural network*.tw.
		11. perceptron*.tw.
		12. connectionist model.tw.
		13. exp Support Vector Machine/
		14. (support vector adj3 (machine or network*)).tw.
		15. (statistic* adj3 (map* or learn*)).tw.
		16. chatbot*.tw.
		17. Virtual private agent*.tw.
		18. virtual intelligent agent*.tw.

19. animated character*.tw.
20. SIRI.tw.
21. Recommendation system*.tw.
22. ((image or face or facial) adj3 recogni*).tw.
23. exp ROBOTICS/
24. robot*.tw.
25. (virtual adj3 assistant*).tw.
26. ((automat* or "computer generated") adj3
decision*).tw.
27. or/1-26
28. exp Decision Making/
29. (decision adj3 (support or making)).tw.
30. exp Decision Support Techniques/
31. patient decision aid.tw.
32. ((practice or decision) adj3 (chang* or alter)).tw.
33. ((patient or consumer or customer) adj3 (choice* or
decision* or decide or choos*)).tw.
34. ((professional or clinic* or manage* or staff) adj3
(choice* or decision* or decide or choos*)).tw.
35. or/28-34
36. meta-analysis/
37. exp review literature/
38. (meta-analy\$ or meta analy\$ or metaanaly\$).tw.

		39. meta analysis.pt.
		40. review academic.pt.
		41. review literature.pt.
		42. letter.pt.
		43. review of reported cases.pt.
		44. historical article.pt.
		45. review multicase.pt.
		46. 36 or 37 or 38 or 39 or 40 or 41
		47. 42 or 43 or 44 or 45
		48. 46 not 47
		49. animal/
		50. human/
		51. 49 and 50
		52. 49 not 51
		53. 48 not 52
		54. 27 and 35 and 53
		55. limit 54 to (english language and yr="2013 -Current")
Medline	Artificial Intelligence RCTs	1. exp Artificial Intelligence/
	KC18	2. (artificial intelligence or AI).tw.
		3. ((comput* or artificial or machine) adj3
		intelligence).tw.
		4. exp Machine Learning/

 5. ((machine or artificial or deep) adj3 learning).tw. 6. exp Algorithms/ 7. algorithm*.tw. 8. (data driven or data-driven).tw. 9. (computer adj3 (assist* or generat*)).tw. 	
7. algorithm*.tw.8. (data driven or data-driven).tw.	
8. (data driven or data-driven).tw.	
9 (computer adi3 (assist* or generat*)) two	
si (comparei aujo (asiste oi generate //tem	
10. neural network*.tw.	
11. perceptron*.tw.	
12. connectionist model.tw.	
13. exp Support Vector Machine/	
14. (support vector adj3 (machine or network*)).tw.	
15. (statistic* adj3 (map* or learn*)).tw.	
16. chatbot*.tw.	
17. Virtual private agent*.tw.	
18. virtual intelligent agent*.tw.	
19. animated character*.tw.	
20. SIRI.tw.	
21. Recommendation system*.tw.	
22. ((image or face or facial) adj3 recogni*).tw.	
23. exp ROBOTICS/	
24. robot*.tw.	
25. (virtual adj3 assistant*).tw.	
26. ((automat* or "computer generated") adj3	
decision*).tw.	

27. or/1-26
28. exp Decision Making/
29. (decision adj3 (support or making)).tw.
30. exp Decision Support Techniques/
31. patient decision aid.tw.
32. ((practice or decision) adj3 (chang* or alter)).tw.
33. ((patient or consumer or customer) adj3 (choice* or
decision* or decide or choos*)).tw.
34. ((professional or clinic* or manage* or staff) adj3
(choice* or decision* or decide or choos*)).tw.
35. or/28-34
36. randomized controlled trial.pt.
37. controlled clinical trial.pt.
38. randomized controlled trials/
39. random allocation/
40. double-blind method/
41. single-blind method/
42. 36 or 37 or 38 or 39 or 40 or 41
43. animal/
44. human/
45. 43 and 44
46. 43 not 45
47. 42 not 46

		48. 27 and 35 and 47
		49. limit 48 to (english language and yr="2013 -Current")
Embase	Artificial Intelligence Reviews1	1. exp artificial intelligence/
		2. (artificial intelligence or AI).tw.
		((comput* or artificial or machine) adj3
		intelligence).tw.
		4. exp machine learning/
		5. ((machine or artificial or deep) adj3 learning).tw.
		6. exp algorithm/
		7. algorithm*.tw.
		8. (data driven or data-driven).tw.
		(computer adj3 (assist* or generat*)).tw.
		10. neural network*.tw.
		11. perceptron*.tw.
		12. connectionist model.tw.
		13. exp support vector machine/
		14. (support vector adj3 (machine or network*)).tw.
		15. (statistic* adj3 (map* or learn*)).tw.
		16. chatbot*.tw.
		17. Virtual private agent*.tw.
		18. virtual intelligent agent*.tw.
		19. animated character*.tw.

20. SIRI.tw.
21. Recommendation system*.tw.
22. ((image or face or facial) adj3 recogni*).tw.
23. exp robotics/
24. robot*.tw.
25. (virtual adj3 assistant*).tw.
26. ((automat* or "computer generated") adj3
decision*).tw.
27. or/1-26
28. exp decision making/
29. (decision adj3 (support or making)).tw.
30. exp decision support system/
31. patient decision aid.tw.
32. ((practice or decision) adj3 (chang* or alter)).tw.
33. ((patient or consumer or customer) adj3 (choice* or
decision* or decide or choos*)).tw.
34. ((professional or clinic* or manage* or staff) adj3
(choice* or decision* or decide or choos*)).tw.
35. or/28-34
36. exp Meta Analysis/
37. ((meta adj analy\$) or metaanalys\$).tw.
38. (systematic adj (review\$1 or overview\$1)).tw.
39. or/36-38

· · · · · · · · · · · · · · · · · · ·	
	40. cancerlit.ab.
	41. cochrane.ab.
	42. embase.ab.
	43. (psyclit or psychlit).ab.
	44. (psycinfo or psychinfo).ab.
	45. (cinahl or cinhal).ab.
	46. science citation index.ab.
	47. bids.ab.
	48. or/40-47
	49. reference lists.ab.
	50. bibliograph\$.ab.
	51. hand-search\$.ab.
	52. manual search\$.ab.
	53. relevant journals.ab.
	54. or/49-53
	55. data extraction.ab.
	56. selection criteria.ab.
	57. 55 or 56
	58. review.pt.
	59. 57 and 58
	60. letter.pt.
	61. editorial.pt.
	62. animal/

		63. human/
		64. 62 not (62 and 63)
		65. or/60-61,64
		66. 39 or 48 or 54 or 59
		67. 66 not 65
		68. 27 and 35 and 67
		69. limit 68 to (english language and yr="2013 -Current")
Embase	Artificial Intelligence RCTs1	1. exp artificial intelligence/
		2. (artificial intelligence or AI).tw.
		3. ((comput* or artificial or machine) adj3
		intelligence).tw.
		4. exp machine learning/
		5. ((machine or artificial or deep) adj3 learning).tw.
		6. exp algorithm/
		7. algorithm*.tw.
		8. (data driven or data-driven).tw.
		9. (computer adj3 (assist* or generat*)).tw.
		10. neural network*.tw.
		11. perceptron*.tw.
		12. connectionist model.tw.
		13. exp support vector machine/
		14. (support vector adj3 (machine or network*)).tw.

15. (statistic* adj3 (map* or learn*)).tw.
16. chatbot*.tw.
17. Virtual private agent*.tw.
18. virtual intelligent agent*.tw.
19. animated character*.tw.
20. SIRI.tw.
21. Recommendation system*.tw.
22. ((image or face or facial) adj3 recogni*).tw.
23. exp robotics/
24. robot*.tw.
25. (virtual adj3 assistant*).tw.
26. ((automat* or "computer generated") adj3
decision*).tw.
27. or/1-26
28. exp decision making/
29. (decision adj3 (support or making)).tw.
30. exp decision support system/
31. patient decision aid.tw.
32. ((practice or decision) adj3 (chang* or alter)).tw.
33. ((patient or consumer or customer) adj3 (choice* or
decision* or decide or choos*)).tw.
34. ((professional or clinic* or manage* or staff) adj3
(choice* or decision* or decide or choos*)).tw.

35. or/28-34
36. Clinical Trial/
37. Randomized Controlled Trial/
38. controlled clinical trial/
39. multicenter study/
40. Phase 3 clinical trial/
41. Phase 4 clinical trial/
42. exp RANDOMIZATION/
43. Single Blind Procedure/
44. Double Blind Procedure/
45. Crossover Procedure/
46. PLACEBO/
47. randomi?ed controlled trial\$.tw.
48. rct.tw.
49. (random\$ adj2 allocat\$).tw.
50. single blind\$.tw.
51. double blind\$.tw.
52. ((treble or triple) adj blind\$).tw.
53. placebo\$.tw.
54. Prospective Study/
55. or/36-54
56. Case Study/
57. case report.tw.

	58. abstract report/ or letter/
	59. Conference proceeding.pt.
	60. Conference abstract.pt.
	61. Editorial.pt.
	62. Letter.pt.
	63. Note.pt.
	64. or/56-63
	65. 55 not 64
	66. 27 and 35 and 65
	67. limit 66 to (english language and yr="2013 -Current")
Artificial Intelligence	1. exp Artificial intelligence/
	2. (artificial intelligence or AI).tw.
	3. ((comput* or artificial or machine) adj3
	intelligence).tw.
	4. Machine Learning.tw.
	5. ((machine or artificial or deep) adj3 learning).tw.
	6. exp Algorithms/
	7. algorithm*.tw.
	8. (data driven or data-driven).tw.
	9. (computer adj3 (assist* or generat*)).tw.
	10. neural network*.tw.
	11. perceptron*.tw.
	Artificial Intelligence

12. connectionist model.tw.
13. (support vector adj3 (machine or network*)).tw.
14. (statistic* adj3 (map* or learn*)).tw.
15. chatbot*.tw.
16. Virtual private agent*.tw.
17. virtual intelligent agent*.tw.
18. animated character*.tw.
19. SIRI.tw.
20. Recommendation system*.tw.
21. ((image or face or facial) adj3 recogni*).tw.
22. robot*.tw.
23. (virtual adj3 assistant*).tw.
24. ((automat* or "computer generated") adj3
decision*).tw.
25. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or
12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or
22 or 23 or 24
26. exp Decision making/
27. (decision adj3 (support or making)).tw.
28. patient decision aid.tw.
29. ((practice or decision) adj3 (chang* or alter)).tw.
30. ((patient or consumer or customer) adj3 (choice* or
decision* or decide or choos*)).tw.

31. ((professional or clinic* or manage* or staff) adj3
(choice* or decision* or decide or choos*)).tw.
32. 26 or 27 or 28 or 29 or 30 or 31
33. 25 and 32
34. limit 33 to yr="2013 -Current"

CINAHL Artificial Intelligence Reviews

Search Terms	Search Options	Actions
S24	S14 AND S22	Limiters - Published Date: 20130101-20181031; English Language; Publication Type: Review Search modes - Boolean/Phrase
S23	S14 AND S22	Search modes - Boolean/Phrase
S22	S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21	Search modes - Boolean/Phrase
S21	TX professional N2 decision OR TX management N2 decision OR TX clinic* N2 decision	Search modes - Boolean/Phrase
S20	TX practice N2 chang* OR TX decision N2 chang*	Search modes - Boolean/Phrase
S19	TX patient decision aid	Search modes - Boolean/Phrase
S18	(MM "Decision Making, Patient")	Search modes - Boolean/Phrase
S17	(MM "Decision Support Systems, Clinical") OR (MM "Decision Support Systems, Management") OR (MM "Decision Support Techniques")	Search modes - Boolean/Phrase
S16	TX decision N2 support OR TX decision N2 mak*	Search modes - Boolean/Phrase

S15	(MM "Decision Making, Computer Assisted") OR (MM "Decision Making") OR (MM "Decision Making, Clinical")	Search modes - Boolean/Phrase
S14	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13	Search modes - Boolean/Phrase
S13	TX Recommendation system*	Search modes - Boolean/Phrase
S12	TX image N2 recognition OR TX fac* N2 recognition	Search modes - Boolean/Phrase
S11	TX data driven	Search modes - Boolean/Phrase
S10	TX support vector N2 machine	Search modes - Boolean/Phrase
S9	TX Virtual private agent* OR TX virtual intelligent agent* OR TX virtual N2 assistant*	Search modes - Boolean/Phrase
S8	TX SIRI OR TX chatbot OR TX animated character*	Search modes - Boolean/Phrase
S7	TX connectionist model	Search modes - Boolean/Phrase
S6	TX perceptron*	Search modes - Boolean/Phrase
S5	TX neural network*	Search modes - Boolean/Phrase
S4	TX computer N2 assist* OR TX computer N2 generat*	Search modes - Boolean/Phrase
S3	TX Machine Learning OR TX computer intelligence OR TX algorithm*	Search modes - Boolean/Phrase
S2	TX artificial intelligence	Search modes - Boolean/Phrase
S1	(MM "Artificial Intelligence")	Search modes - Boolean/Phrase

CINAHL Artificial Intelligence RCTs

Search ID# Search Terms

S24 S14 AND S22

Search Options

Limiters - Published Date: 20130101-20181031; English Language; Randomized Controlled Trials

		Search modes - Boolean/Phrase
S23	S14 AND S22	Search modes - Boolean/Phrase
S22	S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21	Search modes - Boolean/Phrase
S21	TX professional N2 decision OR TX management N2 decision OR TX clinic* N2 decision	Search modes - Boolean/Phrase
S20	TX practice N2 chang* OR TX decision N2 chang*	Search modes - Boolean/Phrase
S19	TX patient decision aid	Search modes - Boolean/Phrase
S18	(MM "Decision Making, Patient")	Search modes - Boolean/Phrase
S17	(MM "Decision Support Systems, Clinical") OR (MM "Decision Support Systems, Management") OR (MM "Decision Support Techniques")	Search modes - Boolean/Phrase
S16	TX decision N2 support OR TX decision N2 mak*	Search modes - Boolean/Phrase
S15	(MM "Decision Making, Computer Assisted") OR (MM "Decision Making") OR (MM "Decision Making, Clinical")	Search modes - Boolean/Phrase
S14	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13	Search modes - Boolean/Phrase
S13	TX Recommendation system*	Search modes - Boolean/Phrase
S12	TX image N2 recognition OR TX fac* N2 recognition	Search modes - Boolean/Phrase
S11	TX data driven	Search modes - Boolean/Phrase
S10	TX support vector N2 machine	Search modes - Boolean/Phrase
S9	TX Virtual private agent* OR TX virtual intelligent agent* OR TX virtual N2 assistant*	Search modes - Boolean/Phrase
S8	TX SIRI OR TX chatbot OR TX animated character*	Search modes - Boolean/Phrase
S7	TX connectionist model	Search modes - Boolean/Phrase

S6	TX perceptron*	Search modes - Boolean/Phrase
S5	TX neural network*	Search modes - Boolean/Phrase
S4	TX computer N2 assist* OR TX computer N2 generat*	Search modes - Boolean/Phrase
S3	TX Machine Learning OR TX computer intelligence OR TX algorithm*	Search modes - Boolean/Phrase
S2	TX artificial intelligence	Search modes - Boolean/Phrase
S1	(MM "Artificial Intelligence")	Search modes - Boolean/Phrase
Health Busin	iess Elite	
Search ID#	Search Terms	Search Options
S24	S14 AND S21	Limiters - Publication Type: Periodical; Published Date: 20130101- 20181031 Search modes - Boolean/Phrase
S23	S14 AND S21	Limiters - Publication Type: Periodical; Published Date: 20130101- 20181031 Search modes - Boolean/Phrase
S22	S14 AND S21	Search modes - Boolean/Phrase
S21	S15 OR S16 OR S17 OR S18 OR S19 OR S20	Search modes - Boolean/Phrase
S20	TX professional N2 decision OR TX management N2 decision OR TX clinic* N2 decision	2 Search modes - Boolean/Phrase
S19	TX practice N2 chang* OR TX decision N2 chang*	Search modes - Boolean/Phrase
S18	TX patient decision aid	Search modes - Boolean/Phrase
S17	SU Decision Support System	Search modes - Boolean/Phrase
S16	TX decision N2 support OR TX decision N2 mak*	Search modes - Boolean/Phrase
S15	SU Decision Making	Search modes - Boolean/Phrase

S14	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12	Search modes - Boolean/Phrase
	OR \$13	

S13	TX Recommendation system*	Search modes - Boolean/Phrase
S12	TX image N2 recognition OR TX fac* N2 recognition	Search modes - Boolean/Phrase
S11	TX data driven	Search modes - Boolean/Phrase
S10	TX support vector N2 machine	Search modes - Boolean/Phrase
S9	TX Virtual private agent* OR TX virtual intelligent agent* OR TX virtual N2 assistant*	Search modes - Boolean/Phrase
S8	TX SIRI OR TX chatbot OR TX animated character*	Search modes - Boolean/Phrase
S7	TX connectionist model	Search modes - Boolean/Phrase
S6	TX perceptron*	Search modes - Boolean/Phrase
S5	TX neural network*	Search modes - Boolean/Phrase
S4	TX computer N2 assist* OR TX computer N2 generat*	Search modes - Boolean/Phrase
S3	TX Machine Learning OR TX computer intelligence OR TX algorithm*	Search modes - Boolean/Phrase
S2	TX artificial intelligence	Search modes - Boolean/Phrase
S1	SU artificial intelligence	Search modes - Boolean/Phrase

PsychInfo Artificial Intelligence Reviews

S14	Limiters - Publication Year: 2013-2018; Language: English; Methodology:	<u>View Results</u> (119)
AND	LITERATURE REVIEW; Exclude Dissertations	<u>View Details</u>
S21	Search modes - Boolean/Phrase	<u>Edit</u>
S22	S14 AND S21	Search modes - Boolean/Phrase
S21	S15 OR S16 OR S17 OR S18 OR S19 OR S20	Search modes - Boolean/Phrase

S20	TX professional N2 decision OR TX management N2 decision OR TX clinic* N2 decision	Search modes - Boolean/Phrase
S19	TX patient decision aid	Search modes - Boolean/Phrase
S18	MJ decision aid	Search modes - Boolean/Phrase
S17	MJ decision support	Search modes - Boolean/Phrase
S16	TX decision N2 support OR TX decision N2 mak*	Search modes - Boolean/Phrase
S15	MJ decision making	Search modes - Boolean/Phrase
S14	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13	Search modes - Boolean/Phrase
S13	TX Recommendation system*	Search modes - Boolean/Phrase
S12	TX image N2 recognition OR TX fac* N2 recognition	Search modes - Boolean/Phrase
S11	TX data driven	Search modes - Boolean/Phrase
S10	TX support vector N2 machine	Search modes - Boolean/Phrase
S9	TX Virtual private agent* OR TX virtual intelligent agent* OR TX virtual N2 assistant*	Search modes - Boolean/Phrase
S8	TX SIRI OR TX chatbot OR TX animated character*	Search modes - Boolean/Phrase
S7	TX connectionist model	Search modes - Boolean/Phrase
S6	TX perceptron*	Search modes - Boolean/Phrase
S5	TX neural network*	Search modes - Boolean/Phrase
S4	TX computer N2 assist* OR TX computer N2 generat*	Search modes - Boolean/Phrase
S3	TX Machine Learning OR TX computer intelligence OR TX algorithm*	Search modes - Boolean/Phrase
S2	TX artificial intelligence	Search modes - Boolean/Phrase

S1 MJ Artificial Intelligence

Search modes - Boolean/Phrase

Proquest Public Health and ASSIA

((((((artificial intelligence) OR ft(artificial intelligence) OR ft(Machine Learning) OR ft(computer intelligence) OR ft(algorithm) OR ft(neural network) OR ft(perceptron) OR ft(connectionist model) OR ft(SIRI) OR ft(chatbot)) AND at.exact("Literature Review" OR "Review")) AND la.exact("English")) AND at.exact("Literature Review" OR "Review")) AND la.exact("English")) AND at.exact("Literature Review" OR "Review")) AND la.exact("English"))